393 related articles for article (PubMed ID: 1646325)
21. Role of nitric oxide/cyclic GMP in i.c.v. administered beta-endorphin- and (+)-cis-dioxolane-induced antinociception in the mouse.
Xu JY; Tseng LF
Eur J Pharmacol; 1994 Sep; 262(3):223-31. PubMed ID: 7813587
[TBL] [Abstract][Full Text] [Related]
22. mu/delta Cooperativity and opposing kappa-opioid effects in nucleus accumbens-mediated antinociception in the rat.
Schmidt BL; Tambeli CH; Levine JD; Gear RW
Eur J Neurosci; 2002 Mar; 15(5):861-8. PubMed ID: 11906528
[TBL] [Abstract][Full Text] [Related]
23. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
[TBL] [Abstract][Full Text] [Related]
24. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.
Ko MC; Johnson MD; Butelman ER; Willmont KJ; Mosberg HI; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1113-20. PubMed ID: 10565831
[TBL] [Abstract][Full Text] [Related]
25. Relative analgesic potency of mu, delta and kappa opioids after spinal administration in amphibians.
Stevens CW
J Pharmacol Exp Ther; 1996 Feb; 276(2):440-8. PubMed ID: 8632308
[TBL] [Abstract][Full Text] [Related]
26. Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1993 Sep; 266(3):1430-8. PubMed ID: 8103794
[TBL] [Abstract][Full Text] [Related]
27. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
[TBL] [Abstract][Full Text] [Related]
28. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies.
Devine DP; Leone P; Pocock D; Wise RA
J Pharmacol Exp Ther; 1993 Sep; 266(3):1236-46. PubMed ID: 7690399
[TBL] [Abstract][Full Text] [Related]
29. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
30. Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain.
Rothman RB; Bykov V; de Costa BR; Jacobson AE; Rice KC; Brady LS
Peptides; 1990; 11(2):311-31. PubMed ID: 2162533
[TBL] [Abstract][Full Text] [Related]
31. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
[TBL] [Abstract][Full Text] [Related]
32. Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.
Heyman JS; Mulvaney SA; Mosberg HI; Porreca F
Brain Res; 1987 Sep; 420(1):100-8. PubMed ID: 2823970
[TBL] [Abstract][Full Text] [Related]
33. Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception.
Rady JJ; Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1991 Feb; 256(2):448-57. PubMed ID: 1847196
[TBL] [Abstract][Full Text] [Related]
34. Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.
Ko MC; Butelman ER; Traynor JR; Woods JH
J Pharmacol Exp Ther; 1998 May; 285(2):518-26. PubMed ID: 9580592
[TBL] [Abstract][Full Text] [Related]
35. Different motor actions of dynorphins and nonpeptide kappa opioid receptor agonists in the isolated rat colon.
Scheurer U; Wenger F; Caliezi A; Drack E; Varga L; Halter F
J Pharmacol Exp Ther; 1990 Mar; 252(3):1324-30. PubMed ID: 1969475
[TBL] [Abstract][Full Text] [Related]
36. Spinal opioid delta antinociception in the mouse: mediation by a 5'-NTII-sensitive delta receptor subtype.
Mattia A; Farmer SC; Takemori AE; Sultana M; Portoghese PS; Mosberg HI; Bowen WD; Porreca F
J Pharmacol Exp Ther; 1992 Feb; 260(2):518-25. PubMed ID: 1310737
[TBL] [Abstract][Full Text] [Related]
37. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes.
Sofuoglu M; Portoghese PS; Takemori AE
J Pharmacol Exp Ther; 1991 May; 257(2):676-80. PubMed ID: 1851833
[TBL] [Abstract][Full Text] [Related]
38. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.
Welch SP
J Pharmacol Exp Ther; 1993 May; 265(2):633-40. PubMed ID: 8388455
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.
Steinmiller CL; Young AM
Psychopharmacology (Berl); 2008 Jan; 195(4):497-507. PubMed ID: 17882404
[TBL] [Abstract][Full Text] [Related]
40. The effect of pretreatment with a delta 2-opioid receptor antisense oligodeoxynucleotide on the recovery from acute antinociceptive tolerance to delta 2-opioid receptor agonist in the mouse spinal cord.
Narita M; Mizoguchi H; Kampine JP; Tseng LF
Br J Pharmacol; 1997 Feb; 120(4):587-92. PubMed ID: 9051295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
